Term Sheet
To prospectus dated November 14, 2011,
prospectus supplement dated November 14, 2011 and
product supplement no. 4-I dated November 14, 2011
|
Term Sheet to
Product Supplement No. 4-I
Registration Statement No. 333-177923
Dated April 22, 2013; Rule 433
|
|
Structured
Investments
|
$
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks due May 14, 2014
|
·
|
The notes are designed for investors who seek exposure to the performance of an equally weighted basket of 15 Reference Stocks, subject to the Basket Adjustment Factor. Investors should be willing to forgo interest and dividend payments and, if the Basket declines or if the Ending Basket Level is not greater than the Starting Basket Level by at least approximately 1.01%, be willing to lose some or all of their principal. Any payment on the notes is subject to the credit risk of JPMorgan Chase & Co.
|
·
|
Unsecured and unsubordinated obligations of JPMorgan Chase & Co. maturing May 14, 2014*
|
·
|
Minimum denominations of $10,000 and integral multiples of $1,000 in excess thereof
|
·
|
The notes are expected to price on or about April 26, 2013 and are expected to settle on or about May 1, 2013.
|
Basket:
|
The Basket consists of 15 common stocks or American Depositary Shares (“ADSs”) (each, a “Reference Stock” and collectively, the “Reference Stocks”). The issuers of the Reference Stocks and the Bloomberg ticker symbol, the relevant exchange, the Stock Weight and the Initial Stock Price of each Reference Stock are set forth under “The Basket” on page TS-1 of this term sheet.
|
|
Payment at Maturity:
|
Payment at maturity will reflect the performance of the Basket, subject to the Basket Adjustment Factor. Accordingly, at maturity, you will receive an amount per $1,000 principal amount note calculated as follows:
$1,000 × (1 + Basket Return) × Basket Adjustment Factor
Because the Basket Adjustment Factor is 99.00%, you will lose some or all of your investment at maturity if the Basket Return is less than approximately 1.01%. For more information on how the Basket Adjustment Factor can impact your payment at maturity, please see “What Is the Total Return on the Notes at Maturity, Assuming a Range of Performances for the Basket?” in this term sheet.
|
|
Basket Return:
|
Ending Basket Level – Starting Basket Level
Starting Basket Level
|
|
Basket Adjustment Factor:
|
99.00%
|
|
Starting Basket Level:
|
Set equal to 100 on the pricing date
|
|
Ending Basket Level:
|
The Basket Closing Level on the Observation Date
|
|
Basket Closing Level:
|
The Basket Closing Level will be calculated as follows:
100 × [1 + sum of (Stock Return of each Reference Stock × 1/15)]
|
|
Stock Return:
|
Final Stock Price – Initial Stock Price
Initial Stock Price
|
|
Initial Stock Price:
|
With respect to each Reference Stock, the closing price of one share of that Reference Stock on the pricing date, as specified in “The Basket” on page TS-1 of this term sheet, divided by the applicable Stock Adjustment Factor
|
|
Final Stock Price:
|
With respect to each Reference Stock, the closing price of one share of that Reference Stock on the Observation Date
|
|
Stock Adjustment Factor:
|
With respect to each Reference Stock, set initially at 1.0 on the pricing date and subject to adjustment under certain circumstances. See “General Terms of Notes — Additional Reference Stock Provisions — A. Anti-Dilution Adjustments” in the accompanying product supplement no. 4-I for further information.
|
|
Observation Date*:
|
May 9, 2014
|
|
Maturity Date*:
|
May 14, 2014
|
|
CUSIP:
|
48126D2P3
|
*
|
Subject to postponement in the event of a market disruption event and as described under “Description of Notes — Payment at Maturity” and “Description of Notes — Postponement of a Determination Date — B. Notes Linked to a Basket” in the accompanying product supplement no. 4-I
|
Price to Public (1)
|
Fees and Commissions (2)
|
Proceeds to Issuer
|
|
Per note
|
$1,000
|
$
|
$
|
Total
|
$
|
$
|
$
|
(1)
|
See “Supplemental Use of Proceeds” in this term sheet for information about the components of the price to public of the notes.
|
(2)
|
J.P. Morgan Securities LLC, which we refer to as JPMS, acting as agent for JPMorgan Chase & Co., will pay all of the selling commissions it receives from us to other affiliated or unaffiliated dealers. In no event will these selling commissions exceed $10.00 per $1,000 principal amount note. See “Plan of Distribution (Conflicts of Interest)” beginning on page PS-77 of the accompanying product supplement no. 4-I.
|
|
·
|
Product supplement no. 4-I dated November 14, 2011:
|
|
·
|
Prospectus supplement dated November 14, 2011:
|
|
·
|
Prospectus dated November 14, 2011:
|
Ticker Symbol
|
Reference Stock Issuer
|
Relevant Exchange
|
Stock Weight
|
Initial Stock Price*
|
AAPL
|
Apple Inc.
|
The NASDAQ Stock Market (NASDAQ)
|
1/15
|
$
|
C
|
Citigroup Inc.
|
New York Stock Exchange (NYSE)
|
1/15
|
$
|
YUM
|
Yum! Brands, Inc.
|
NYSE
|
1/15
|
$
|
GM
|
General Motors Company
|
NYSE
|
1/15
|
$
|
KO
|
The Coca-Cola Company
|
NYSE
|
1/15
|
$
|
COH
|
Coach, Inc.
|
NYSE
|
1/15
|
$
|
SBUX
|
Starbucks Corporation
|
NASDAQ
|
1/15
|
$
|
MJN
|
Mead Johnson Nutrition Company
|
NYSE
|
1/15
|
$
|
NKE
|
NIKE, Inc. (Class B Common Stock)
|
NYSE
|
1/15
|
$
|
MDLZ
|
Mondelēz International, Inc. (Class A Common Stock)
|
NASDAQ
|
1/15
|
$
|
WYNN
|
Wynn Resorts, Limited
|
NASDAQ
|
1/15
|
$
|
HOT
|
Starwood Hotels & Resorts Worldwide, Inc.
|
NYSE
|
1/15
|
$
|
TEVA
|
Teva Pharmaceutical Industries Limited. (ADS)
|
NYSE
|
1/15
|
$
|
BRCM
|
Broadcom Corporation (Class A Common Stock)
|
NASDAQ
|
1/15
|
$
|
HBC
|
HSBC Holdings plc (ADS)
|
NYSE
|
1/15
|
$
|
JPMorgan Structured Investments —
|
TS-1
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
Ending Basket Level
|
Basket Return
|
Total Return
|
200.00
|
100.00%
|
98.00%
|
190.00
|
90.00%
|
88.10%
|
180.00
|
80.00%
|
78.20%
|
170.00
|
70.00%
|
68.30%
|
160.00
|
60.00%
|
58.40%
|
150.00
|
50.00%
|
48.50%
|
140.00
|
40.00%
|
38.60%
|
130.00
|
30.00%
|
28.70%
|
120.00
|
20.00%
|
18.80%
|
110.00
|
10.00%
|
8.90%
|
105.00
|
5.00%
|
3.95%
|
101.01
|
1.01%
|
0.00%
|
100.50
|
0.50%
|
-0.51%
|
100.00
|
0.00%
|
-1.00%
|
95.00
|
-5.00%
|
-5.95%
|
90.00
|
-10.00%
|
-10.90%
|
80.00
|
-20.00%
|
-20.80%
|
70.00
|
-30.00%
|
-30.70%
|
60.00
|
-40.00%
|
-40.60%
|
50.00
|
-50.00%
|
-50.50%
|
40.00
|
-60.00%
|
-60.40%
|
30.00
|
-70.00%
|
-70.30%
|
20.00
|
-80.00%
|
-80.20%
|
10.00
|
-90.00%
|
-90.10%
|
0.00
|
-100.00%
|
-100.00%
|
JPMorgan Structured Investments —
|
TS-2
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
|
·
|
UNCAPPED INVESTMENT EXPOSURE TO THE PERFORMANCE OF THE BASKET — The notes provide uncapped exposure to the performance of the Basket, subject to the Basket Adjustment Factor. Because the notes are our unsecured and unsubordinated obligations, payment of any amount at maturity is subject to our ability to pay our obligations as they become due.
|
|
·
|
RETURN LINKED TO AN EQUALLY WEIGHTED BASKET OF 15 REFERENCE STOCKS — The return on the notes is linked to the performance of an equally weighted Basket that consists of 15 Reference Stocks as set forth under “The Basket” on page TS-1 of this term sheet.
|
|
·
|
CAPITAL GAINS TAX TREATMENT — You should review carefully the section entitled “Material U.S. Federal Income Tax Consequences” in the accompanying product supplement no. 4-I. The following discussion, when read in combination with that section, constitutes the full opinion of our special tax counsel, Davis Polk & Wardwell LLP, regarding the material U.S. federal income tax consequences of owning and disposing of notes.
Based on current market conditions, in the opinion of our special tax counsel it is reasonable to treat the notes as “open transactions” that are not debt instruments for U.S. federal income tax purposes. Assuming this treatment is respected, the gain or loss on your notes should be treated as long-term capital gain or loss if you hold your notes for more than a year, whether or not you are an initial purchaser of notes at the issue price. However, the Internal Revenue Service (the “IRS”) or a court may not respect this treatment of the notes, in which case the timing and character of any income or loss on the notes could be materially and adversely affected. In addition, in 2007 Treasury and the IRS released a notice requesting comments on the U.S. federal income tax treatment of “prepaid forward contracts” and similar instruments. The notice focuses in particular on whether to require investors in these instruments to accrue income over the term of their investment. It also asks for comments on a number of related topics, including the character of income or loss with respect to these instruments; the relevance of factors such as the nature of the underlying property to which the instruments are linked; the degree, if any, to which income (including any mandated accruals) realized by non-U.S. investors should be subject to withholding tax; and whether these instruments are or should be subject to the “constructive ownership” regime, which very generally can operate to recharacterize certain long-term capital gain as ordinary income and impose a notional interest charge. While the notice requests comments on appropriate transition rules and effective dates, any Treasury regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the tax consequences of an investment in the notes, possibly with retroactive effect. You should consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the notes, including possible alternative treatments and the issues presented by this notice.
Non-U.S. Holders – Additional Tax Consideration
Non-U.S. Holders should note that recently proposed Treasury regulations, if finalized in their current form, could impose a withholding tax at a rate of 30% (subject to reduction under an applicable income tax treaty) on amounts attributable to U.S.-source dividends (including, potentially, adjustments to account for extraordinary dividends) that are paid or “deemed paid” after December 31, 2013 under certain financial instruments, if certain other conditions are met. While significant aspects of the application of these proposed regulations to the notes are uncertain, if these proposed regulations were finalized in their current form, we (or other withholding agents) might determine that withholding is required with respect to notes held by a Non-U.S. Holder or that the Non-U.S. Holder must provide information to establish that withholding is not required. Non-U.S. Holders should consult their tax advisers regarding the potential application of these proposed regulations. If withholding is required, we will not be required to pay any additional amounts with respect to amounts so withheld.
|
|
·
|
YOUR INVESTMENT IN THE NOTES MAY RESULT IN A LOSS — The notes do not guarantee any return of your principal. The amount payable at maturity, if any, will reflect the performance of the Reference Stocks, subject to a reduction by the Basket Adjustment Factor. Because the Basket Adjustment Factor reduces the payment at maturity, if the Ending Basket Level is not greater than the Starting Basket Level by at least approximately 1.01%, you will lose some or all of your investment in the notes.
|
|
·
|
THE BASKET ADJUSTMENT FACTOR WILL DIMINISH ANY INCREASE IN THE VALUE OF THE BASKET AND MAGNIFY ANY DECLINE IN THE VALUE OF BASKET — If the Basket Return is negative or is less than approximately 1.01%, at maturity, you will lose some or all of your investment. In addition, the Basket Adjustment Factor will diminish any increase in the value of the Basket and magnify any decline in the value of the Basket. For each 1% that the Ending Basket Level is greater than the Starting Basket Level, the return on your investment will increase by less than 1%. In addition, for each 1% that the Ending Basket Level is less than the Starting Basket Level, you will lose more than 1% of your investment in the notes, provided that the payment at maturity will not be less than zero.
|
|
·
|
CREDIT RISK OF JPMORGAN CHASE & CO. — The notes are subject to the credit risk of JPMorgan Chase & Co., and our credit ratings and credit spreads may adversely affect the market value of the notes. Investors are dependent on JPMorgan Chase & Co.’s ability to pay all amounts due on the notes. Any actual or potential change in our
|
JPMorgan Structured Investments —
|
TS-3
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
|
|
creditworthiness or credit spreads, as determined by the market for taking our credit risk, is likely to adversely affect the value of the notes. If we were to default on our payment obligations, you may not receive any amounts owed to you under the notes and you could lose your entire investment.
|
|
·
|
POTENTIAL CONFLICTS — We and our affiliates play a variety of roles in connection with the issuance of the notes, including acting as calculation agent and as an agent of the offering of the notes, hedging our obligations under the notes and making the assumptions used to determine the pricing of the notes and the estimated value of the notes when the terms of the notes are set, which we refer to as JPMS’s estimated value. In performing these duties, our economic interests and the economic interests of the calculation agent and other affiliates of ours are potentially adverse to your interests as an investor in the notes. In addition, JPMorgan Chase Bank, National Association, our affiliate, serves as depositary for the ADSs of Teva Pharmaceuticals Industries Limited. As a result, JPMorgan Chase Bank, National Association’s interests, as depositary for the ADSs, may be adverse to your interests as a holder of the notes. Furthermore, our business activities, including hedging and trading activities, could cause our economic interests to be adverse to yours and could adversely affect any payment on the notes and the value of the notes. It is possible that hedging or trading activities of ours or our affiliates in connection with the notes could result in substantial returns for us or our affiliates while the value of the notes declines. Please refer to “Risk Factors — Risks Relating to the Notes Generally” in the accompanying product supplement no. 4-I for additional information about these risks.
We and/or our affiliates may also currently or from time to time engage in business with the Reference Stock issuers, including extending loans to, or making equity investments in, the Reference Stock issuers or providing advisory services to the Reference Stock issuers. In addition, one or more of our affiliates may publish research reports or otherwise express opinions with respect to the Reference Stock issuers, and these reports may or may not recommend that investors buy or hold the Reference Stocks. As a prospective purchaser of the notes, you should undertake an independent investigation of the Reference Stock issuers that in your judgment is appropriate to make an informed decision with respect to an investment in the notes.
|
|
·
|
JPMS’S ESTIMATED VALUE OF THE NOTES WILL BE LOWER THAN THE ORIGINAL ISSUE PRICE (PRICE TO PUBLIC) OF THE NOTES — JPMS’s estimated value is only an estimate using several factors. The original issue price of the notes will exceed JPMS’s estimated value because costs associated with selling, structuring and hedging the notes are included in the original issue price of the notes. These costs include the selling commissions, the projected profits that our affiliates expect to realize for assuming risks inherent in hedging our obligations under the notes and the estimated cost of hedging our obligations under the notes. See “JPMS’s Estimated Value of the Notes” in this term sheet.
|
|
·
|
JPMS’S ESTIMATED VALUE DOES NOT REPRESENT FUTURE VALUES OF THE NOTES AND MAY DIFFER FROM OTHERS’ ESTIMATES — JPMS’s estimated value of the notes is determined by reference to JPMS’s internal pricing models when the terms of the notes are set. This estimated value is based on market conditions and other relevant factors existing at that time and JPMS’s assumptions about market parameters, which can include volatility, dividend rates, interest rates and other factors. Different pricing models and assumptions could provide valuations for notes that are greater than or less than JPMS’s estimated value. In addition, market conditions and other relevant factors in the future may change, and any assumptions may prove to be incorrect. On future dates, the value of the notes could change significantly based on, among other things, changes in market conditions, our creditworthiness, interest rate movements and other relevant factors, which may impact the price, if any, at which JPMS would be willing to buy notes from you in secondary market transactions. See “JPMS’s Estimated Value of the Notes” in this term sheet.
|
|
·
|
JPMS’S ESTIMATED VALUE IS NOT DETERMINED BY REFERENCE TO CREDIT SPREADS FOR OUR CONVENTIONAL FIXED-RATE DEBT — The internal funding rate used in the determination of JPMS’s estimated value generally represents a discount from the credit spreads for our conventional fixed-rate debt. If JPMS were to use the interest rate implied by our conventional fixed-rate credit spreads, we would expect the economic terms of the notes to be more favorable to you. Consequently, our use of an internal funding rate would have an adverse effect on the terms of the notes and any secondary market prices of the notes. See “JPMS’s Estimated Value of the Notes” in this term sheet.
|
|
·
|
THE VALUE OF THE NOTES AS PUBLISHED BY JPMS (AND WHICH MAY BE REFLECTED ON CUSTOMER ACCOUNT STATEMENTS) WILL LIKELY BE HIGHER THAN JPMS’S THEN-CURRENT ESTIMATED VALUE OF THE NOTES FOR A LIMITED TIME PERIOD — We generally expect that some of the costs included in the original issue price of the notes will be partially paid back to you in connection with any repurchases of your notes by JPMS in an amount that will decline to zero over an initial predetermined period. These costs can include projected hedging profits and, in some circumstances, estimated hedging costs and our secondary market credit spreads for structured debt issuances. See “Secondary Market Prices of the Notes” in this term sheet for additional information relating to this initial period. Accordingly, the estimated value of your notes during this initial period will likely be lower than the value of the notes as published by JPMS (and which may be shown on your customer account statements).
|
|
·
|
SECONDARY MARKET PRICES OF THE NOTES WILL LIKELY BE LOWER THAN THE ORIGINAL ISSUE PRICE OF THE NOTES — Any secondary market prices of the notes will likely be lower than the original issue price of the notes because, among other things, secondary market prices take into account our secondary market credit spreads for structured debt issuances and, also, because secondary market prices (a) exclude selling commissions and (b) may exclude projected hedging profits and estimated hedging costs that are included in the original issue price of the notes. As a result, the price, if any, at which JPMS will be willing to buy notes from you in secondary market transactions, if at all, is likely to be lower than the original issue
|
JPMorgan Structured Investments —
|
TS-4
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
|
|
price. Any sale by you prior to the maturity date could result in a substantial loss to you. See the immediately following risk consideration for information about additional factors that will impact any secondary market prices of the notes.
The notes are not designed to be short-term trading instruments. Accordingly, you should be able and willing to hold your notes to maturity. See “— Lack of Liquidity” below.
|
|
·
|
SECONDARY MARKET PRICES OF THE NOTES WILL BE IMPACTED BY MANY ECONOMIC AND MARKET FACTORS — The secondary market price of the notes during their term will be impacted by a number of economic and market factors, which may either offset or magnify each other, aside from the selling commissions, projected hedging profits, estimated hedging costs and the closing price of one share of each Reference Stock, including:
|
|
·
|
any actual or potential change in our creditworthiness or credit spreads;
|
|
·
|
customary bid-ask spreads for similarly sized trades;
|
|
·
|
secondary market credit spreads for structured debt issuances;
|
|
·
|
the actual and expected volatility in the price of each Reference Stock;
|
|
·
|
the time to maturity of the notes;
|
|
·
|
the correlation (or lack of correlation) in price movements among the Reference Stocks;
|
|
·
|
the dividend rate on each Reference Stock;
|
|
·
|
the occurrence of certain events affecting the issuer of a Reference Stock that may or may not require an adjustment to the applicable Stock Adjustment Factor, including a merger or acquisition;
|
|
·
|
interest and yield rates in the market generally; and
|
|
·
|
a variety of other economic, financial, political, regulatory and judicial events.
|
|
|
Additionally, independent pricing vendors and/or third party broker-dealers may publish a price for the notes, which may also be reflected on customer account statements. This price may be different (higher or lower) than the price of the notes, if any, at which JPMS may be willing to purchase your notes in the secondary market.
|
|
·
|
CORRELATION (OR LACK OF CORRELATION) OF THE REFERENCE STOCKS — The notes are linked to an equally weighted Basket consisting of 15 Reference Stocks. Price movements and performances in the Reference Stocks may or may not be correlated with each other. At a time when the value of one or more of the Reference Stocks increases, the value of the other Reference Stocks may not increase as much or may even decline. Therefore, in calculating the Ending Basket Level, increases in the value of one or more of the Reference Stocks may be moderated, or more than offset, by the lesser increases or declines in the value of the other Reference Stocks. In addition, high correlation of movements in the values of the Reference Stocks during periods of negative returns among the Reference Stocks could have an adverse effect on the payment at maturity on the notes. There can be no assurance that the Ending Basket Level will be higher than the Starting Basket Level.
|
|
·
|
NO OWNERSHIP OR DIVIDEND RIGHTS IN THE REFERENCE STOCKS — As a holder of the notes, you will not have any ownership interest or rights in any of the Reference Stocks, such as voting rights or dividend payments. In addition, the issuers of the Reference Stocks will not have any obligation to consider your interests as a holder of the notes in taking any corporate action that might affect the value of the relevant Reference Stocks and the notes. Because the Basket Adjustment Factor always reduces the Payment at Maturity, your return from an investment in the notes may be less than the return from a direct investment in the Reference Stocks.
|
|
·
|
NO AFFILIATION WITH THE REFERENCE STOCK ISSUERS — We are not affiliated with the issuers of the Reference Stocks. We have not independently verified any of the information about the Reference Stock issuers contained in this term sheet. You should undertake your own investigation into the Reference Stocks and their issuers. We are not responsible for the Reference Stock issuers’ public disclosure of information, whether contained in SEC filings or otherwise.
|
|
·
|
NO INTEREST PAYMENTS — As a holder of the notes, you will not receive any interest payments.
|
|
·
|
LACK OF LIQUIDITY — The notes will not be listed on any securities exchange. JPMS intends to offer to purchase the notes in the secondary market but is not required to do so. Even if there is a secondary market, it may not provide enough liquidity to allow you to trade or sell the notes easily. Because other dealers are not likely to make a secondary market for the notes, the price at which you may be able to trade your notes is likely to depend on the price, if any, at which JPMS is willing to buy the notes.
|
|
·
|
HEDGING AND TRADING IN THE REFERENCE STOCKS — While the notes are outstanding, we or any of our affiliates may carry out hedging activities related to the notes, including in the Reference Stocks or instruments related to the Reference Stocks. We or our affiliates may also trade in the Reference Stocks or instruments related to the Reference Stocks from time to time. Any of these hedging or trading activities as of the pricing date and during the term of the notes could adversely affect our payment to you at maturity. It is possible that such hedging or trading activities could result in substantial returns for us or our affiliates while the value of the notes declines.
|
|
·
|
THE ANTI-DILUTION PROTECTION FOR THE REFERENCE STOCKS IS LIMITED AND MAY BE DISCRETIONARY — The calculation agent will make adjustments to the Stock Adjustment Factor for each Reference Stock for certain corporate events affecting that Reference Stock. However, the calculation agent will not make an adjustment in response to all events that could affect each Reference Stock. If an event occurs that does not require the calculation agent to make an adjustment, the value of the notes may be materially and adversely affected. You should also be aware that the calculation agent may make adjustments in response to events that are not described in the accompanying product supplement to account for any diluting or concentrative effect, but the calculation agent is under no obligation to do so or to consider your interests as a holder of the notes in making these determinations.
|
JPMorgan Structured Investments —
|
TS-5
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
|
·
|
RISKS ASSOCIATED WITH NON-U.S. COMPANIES — An investment in the notes, which are linked in part to the ADSs representing interests in the ordinary shares of Teva Pharmaceutical Industries Limited. (which we refer to as “Teva”), which are issued by an Israeli issuer, or HSBC Holdings plc (which we refer to as “HSBC”), which are issued by a U.K. issuer, involves risks associated with the home countries of Teva and HSBC. The ADSs of Teva and HSBC, which are quoted and traded in U.S. dollars on the New York Stock Exchange, may trade differently from the ordinary shares of Teva quoted and traded in Israeli new shekels on the Tel Aviv Stock Exchange and from the ordinary shares of HSBC quoted and traded in pounds sterling on the London Stock Exchange and in the relevant currencies on other stock exchanges. Non-U.S. companies, such as those in Israel and the United Kingdom, are generally subject to accounting, auditing and financial reporting standards and requirements, and securities trading rules different from those applicable to U.S. reporting companies. Generally, non-U.S. securities markets may be more volatile than U.S. securities markets, and market developments may affect non-U.S. markets differently from U.S. securities markets. Direct or indirect government intervention to stabilize these non-U.S. markets, as well as cross shareholdings in non-U.S. companies, may affect trading prices and volumes in those markets. The prices of securities issued by non-U.S. companies may be affected by political, economic, financial and social factors in the home country of the non-U.S. issuer ( i.e. , Israel or the United Kingdom), including changes in that country’s government, economic and fiscal policies, currency exchange laws or other laws or restrictions. Moreover, the economy of that country may differ favorably or unfavorably from the economy of the United States in such respects as growth of gross national product, rate of inflation, capital reinvestment, resources and self-sufficiency. Such country may be subjected to different and, in some cases, more adverse economic environments.
|
|
·
|
THERE ARE IMPORTANT DIFFERENCES BETWEEN THE RIGHTS OF HOLDERS OF ADSs OF TEVA AND HSBC AND THE RIGHTS OF HOLDERS OF THE ORDINARY SHARES OF TEVA AND HSBC — You should be aware that your return on the notes is linked in part to the price of the ADSs and not the ordinary shares of Teva or the ordinary shares of HSBC. There are important differences between the rights of holders of ADSs and the rights of holders of the ordinary shares. Each ADS is a security evidenced by American depositary receipts that represents one ordinary share of Teva or five ordinary shares of HSBC, as applicable. The ADSs are issued pursuant to a deposit agreement, which sets forth the rights and responsibilities of the ADS depositary, Teva or HSBC (as applicable), and holders of the ADSs, which may be different from the rights of holders of the ordinary shares. For example, each may make distributions in respect of the ordinary shares that are not passed on to the holders of its ADSs. Any such differences between the rights of holders of the ADSs and the rights of holders of the ordinary shares of Teva or HSBC may be significant and may materially and adversely affect the value of the ADSs and, as a result, the notes.
|
|
·
|
THE NOTES ARE SUBJECT TO CURRENCY EXCHANGE RATE RISK — Because the ADSs of Teva and HSBC are quoted and traded in U.S. dollars on the New York Stock Exchange, the ordinary shares of Teva are quoted and traded in Israeli new shekels on the Tel Aviv Stock Exchange and the ordinary shares of HSBC are quoted and traded in British pounds sterling on the London Stock Exchange and in the relevant currencies on other stock exchanges, fluctuations in the exchange rate between currencies in which the relevant ordinary shares are quoted and traded and the U.S. dollar will likely affect the relative value of the ADSs of Teva and the ordinary shares of Teva, and the ADSs of HSBC and the ordinary shares of HSBC, as applicable, in the different currencies, and, as a result, will likely affect the market price of the ADSs trading on the New York Stock Exchange. These trading differences and currency exchange rates may affect the closing prices of the ADSs of Teva and HSBC and accordingly, the market value of the notes. Most foreign currencies, including the Israeli new shekel and the British pound sterling, have been subject to significant fluctuations against the U.S. dollar in the past, and may be subject to significant fluctuations in the future. Previous fluctuations or periods of relative stability in the exchange rates between the Israeli new shekel, the British pound sterling and the U.S. dollar are not necessarily indicative of fluctuations or periods of relative stability in those rates that may occur over the term of the notes. The exchange rates between the currencies in which the relevant ordinary shares are quoted and traded and the U.S. dollar are the result of the supply of, and the demand for, those currencies. Changes in the exchange rate result over time from the interaction of many factors directly or indirectly affecting economic and political conditions in Israel, the United Kingdom, the originating countries of the other currencies in which the ordinary shares of HSBC are quoted and traded and the United States, including economic and political developments in other countries. Of particular importance are rates of inflation, interest rate levels, the balance of payments, any political, civil or military unrest and the extent of governmental surpluses or deficits in these countries, all of which are in turn sensitive to the monetary, fiscal and trade policies pursued by these countries and other jurisdictions important to international trade and finance.
|
|
·
|
THE TERMS AND VALUATION OF THE NOTES WILL BE PROVIDED IN THE PRICING SUPPLEMENT — The final terms of the notes will be based on relevant market conditions when the terms of the notes are set and will be provided in the pricing supplement. In particular, JPMS’s estimated value will be provided in the pricing supplement and may be as low as the minimum value for JPMS’s estimated value set forth on the cover of this term sheet. Accordingly, you should consider your potential investment in the notes based on the minimum value for JPMS’s estimated value.
|
JPMorgan Structured Investments —
|
TS-6
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
JPMorgan Structured Investments —
|
TS-7
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
JPMorgan Structured Investments —
|
TS-8
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
JPMorgan Structured Investments —
|
TS-9
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
JPMorgan Structured Investments —
|
TS-10
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
JPMorgan Structured Investments —
|
TS-11
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
JPMorgan Structured Investments —
|
TS-12
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
JPMorgan Structured Investments —
|
TS-13
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
JPMorgan Structured Investments —
|
TS-14
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
JPMorgan Structured Investments —
|
TS-15
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|
JPMorgan Structured Investments —
|
TS-16
|
Return Notes Linked to an Equally Weighted Basket of 15 Reference Stocks
|